AT&T vs Johnson & Johnson: Revenue, Profit and Business Model
AT&T reported $125.6B of revenue in FY2025 and $22B of net income. Johnson & Johnson reported $94.2B of revenue in FY2025 and $26.8B of net income.
Latest financial snapshot
AT&T
- Latest revenue
- $125.6B (FY2025)
- Net income
- $22B
- Net margin
- 17.5%
- Revenue growth
- -2.9% a year, FY2016–FY2025
Johnson & Johnson
- Latest revenue
- $94.2B (FY2025)
- Net income
- $26.8B
- Net margin
- 28.5%
- Revenue growth
- +3.0% a year, FY2016–FY2025
Financial summary
AT&T
AT&T's financial story is large revenue, large debt and a slow correction. The company funded the $48.5 billion DirecTV purchase in 2015 and the $85.4 billion Time Warner purchase in 2018 largely with borrowing, and net debt passed $180 billion after Time Warner closed. It then reversed course: WarnerMedia was separated in 2022, the dividend was cut, and the remaining 70% DIRECTV stake went to TPG in July 2025 for a $5.6 billion gain. FY2025 revenue was $125.6 billion, with $23.4 billion of total net income, $46.4 billion of adjusted EBITDA and $16.6 billion of free cash flow against $117.4 billion of net debt. Roughly $22 billion a year of capital investment goes mostly into fiber and 5G.
Johnson & Johnson
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.
Revenue and profit by year
AT&T
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $125.6B | $22B | 17.5% | +2.7% | Source |
| FY2024 | $122.3B | $10.9B | 8.9% | -0.1% | Source |
| FY2023 | $122.4B | $14.4B | 11.8% | +1.4% | Source |
| FY2022 | $120.7B | -$8.5B | -7.1% | -9.9% | Source |
| FY2021 | $134B | $20.1B | 15.0% | -6.3% | Source |
| FY2020 | $143.1B | -$5.2B | -3.6% | -21.1% | Source |
| FY2019 | $181.2B | $13.9B | 7.7% | +6.1% | Source |
| FY2018 | $170.8B | $19.4B | 11.3% | +6.4% | Source |
| FY2017 | $160.5B | $29.4B | 18.3% | -2.0% | Source |
| FY2016 | $163.8B | $13B | 7.9% | — | Source |
Johnson & Johnson
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | +6.0% | Source |
| FY2024 | $88.8B | $14.1B | 15.8% | +4.3% | Source |
| FY2023 | $85.2B | $35.2B | 41.3% | +6.5% | Source |
| FY2022 | $80B | $17.9B | 22.4% | +1.6% | Source |
| FY2021 | $78.7B | $20.9B | 26.5% | -4.7% | Source |
| FY2020 | $82.6B | $14.7B | 17.8% | +0.6% | Source |
| FY2019 | $82.1B | $15.1B | 18.4% | +0.6% | Source |
| FY2018 | $81.6B | $15.3B | 18.8% | +6.7% | Source |
| FY2017 | $76.5B | $1.3B | 1.7% | +6.3% | Source |
| FY2016 | $71.9B | $16.5B | 23.0% | — | Source |
Where the revenue comes from
AT&T
- Mobility~71%
Wireless service plans and device sales. Segment revenue was $89.5 billion in 2025, of which $67.4 billion was service revenue and $22.1 billion equipment.
- Business Wireline~14%
Connectivity for businesses, from fiber and dedicated internet to legacy voice and data. Revenue fell to $17.2 billion in 2025 from $18.8 billion in 2024.
- Consumer Wireline~11%
Home broadband, led by AT&T Fiber and AT&T Internet Air. Revenue was $14.2 billion in 2025, with fiber revenue up 17.0% to $8.6 billion.
- Latin America~3%
Wireless service in Mexico. Revenue was $4.4 billion in 2025, up from $4.2 billion, with $145 million of operating income.
Johnson & Johnson
- Innovative Medicine~64%
Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.
- MedTech~36%
MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.
Business model and strategy
AT&T
How it makes money
AT&T runs a capital-intensive network business. It buys licensed wireless spectrum, builds and upgrades cell sites, and trenches fiber, then charges consumers and businesses a monthly fee to use that network. Capital investment was $22.0 billion in 2025 against $125.6 billion of revenue.
Growth strategy
With the US smartphone market saturated, AT&T's growth depends on home internet and on keeping the wireless customers it has. It is building fiber, which passed 32.0 million consumer and business locations at the end of 2025 and carried 10.4 million subscribers, and it sells AT&T Internet Air fixed wireless where fiber is not available.
Competitive advantage
AT&T's advantage is the cost of replicating what it already owns. Its fiber network passed 32.0 million consumer and business locations at the end of 2025, and its mid-band 5G service covers more than 310 million people. Keeping that going took $22.0 billion of capital investment in 2025 alone, which is why the national market has three carriers rather than thirty.
Johnson & Johnson
How it makes money
J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal.
Growth strategy
J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).
Competitive advantage
J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time.
Questions about AT&T vs Johnson & Johnson
Which company has higher revenue — AT&T Inc. or Johnson & Johnson?
AT&T Inc. reported $125.6B (FY2025), while Johnson & Johnson reported $94.2B (FY2025). By last reported revenue, AT&T Inc. is the larger business, with Johnson & Johnson reporting a smaller revenue base.
What is the market cap of AT&T Inc. vs Johnson & Johnson?
AT&T Inc.'s market capitalisation stands at $174.4B, while Johnson & Johnson's is $643.9B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to AT&T Inc..
Which is more financially efficient — AT&T Inc. or Johnson & Johnson?
AT&T Inc. generates $945k / employee in revenue per employee, while Johnson & Johnson generates $669k / employee. AT&T Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do AT&T Inc. and Johnson & Johnson make money?
AT&T Inc. and Johnson & Johnson generate revenue in fundamentally different ways. AT&T Inc.: AT&T runs a capital-intensive network business. Johnson & Johnson: J&J makes money in two ways.
Which company is valued higher relative to revenue — AT&T Inc. or Johnson & Johnson?
On a price-to-sales (P/S) basis, AT&T Inc. trades at 1.4x P/S and Johnson & Johnson at 6.8x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to AT&T Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is AT&T Inc. bigger than Johnson & Johnson?
By last reported revenue, AT&T Inc. ($125.6B (FY2025)) is the larger company compared to Johnson & Johnson ($94.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AT&T vs Johnson & Johnson overview